Safety and Immunogenicity of Sequential Immunization of Inactivated COVID-19 Vaccine and Recombinant COVID-19 Vaccine (Ad5 Vector) inChinese Healthy Adults Aged 60 and Above: a Randomized, Observer-blind,Parallel-controlled Clinical Trial

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad5-nCoV Tianjin CanSino Biotechnology (Primary) ; SARS-COV-2 vaccine-inactivated-Sinovac-Biotech
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics
Acronyms Ad5 Vector

Most Recent Events

12 Aug 2022 Status changed from recruiting to completed.
23 Sep 2021 Planned End Date changed from 2 Mar 2022 to 26 May 2022.
23 Sep 2021 Planned primary completion date changed from 28 Sep 2021 to 26 Nov 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight